Last reviewed · How we verify

NCT05057832: Ustekinumab

Determination of Ustekinumab Levels in Patients With Crohn's Disease

Status unknown Last updated 17 November 2021
What this trial tests

trial in Crohn Disease in 95 participants. Status unknown.

Timeline
1 May 2021
Primary endpoint
1 February 2022
1 February 2022

Quick facts

Lead sponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment95
Start date1 May 2021
Primary completion1 February 2022
Estimated completion1 February 2022
Sites1 location across Spain

Conditions studied

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full company profile →

Who can join

18 and older, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational, prospective, single-center follow-up study carried out with patients from the area of the Virgen de Macarena University Hospital, diagnosed with chronic kidney disease, who started treatment with ustekinumab.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

Other Fundación Pública Andaluza para la gestión de la Investigación en Sevilla trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05057832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing